The Celigo Image Cytometer has been previously used for a wide range of immuno-oncology and immunotherapy studies, demonstrating the great utility of this instrument to assess the activity of cytotoxic immune cells against malignant cells of interest.
For the development of new drugs and the advancement of new cell therapies, pharmaceutical companies have recurred to cytotoxicity assays as a quick way to assess the viability of cell lines in response to an external stimulus.
The ongoing pursuit of novel anti-cancer therapeutics must consider the potential for off-target effects on the immune system.
Establishing a High-throughput Screening Platform for NK mediated Cytotoxicity using Image Cytometry
Researchers highlight the need for large-scale screening of cytotoxic cells and their ability to kill target cell lines in both a 2D and 3D fashion.
Syngeneic tumor models and human immune cell-engrafted mice are two of the popular preclinical tools in immuno-oncology studies.
Directly image and count calcein AM-labeled target cells in a 96-well plate using Celigo image cytometer. Concurrent imaging and analysis in 8 minutes.
This webinar explores options for researchers to perform high-throughput cell counting through assays such as MTT, Cell-Titer Glo and manually counting.
June 11-13, 2018 | Boston, MA Learn more
By directly imaging and counting every cell in a well over a course of a drug treatment, the Celigo can perform the cytotoxicity assays in a label-free format.
The University of Kentucky investigated progesterone receptor membrane component 1 (PGRMC1), an often upregulated component in thyroid, breast, colon and lung tumors. PGRMC1 has been associated with drug resistance and is thought of as an indicator of prognosis. The researchers employed a variety of cell types to represent head and neck cancers, as well as oral, lung and ovarian cancers. These cells were exposed to PGRMC1 inhibitors. The Cellometer performed cell counts with Trypan Blue. The PGRMC1 inhibitors successfully prompted cancer stem cell death even when other anti-cancer agents did not. The researchers suggest using PGRMC1 as a cancer stem [...]